W Roosen

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The development path described for JNJ-26489112 provides perspectives on interpretation of retinal effects observed in nonclinical studies and their implications for clinical development. JNJ-26489112 is a CNS-active investigational drug that has potential as a novel treatment for treatment-resistant and bipolar depression, epilepsy, and(More)
  • 1